

Actuarial work, with traceable evidence

Reserving, pricing and valuation workflows that
give qualified actuaries more time for
judgement.

[Explore capabilities →](#)

[Business value →](#)

[Genellipse.com](https://www.genellipse.com)

info@genellipse.com

AegisNow and the Genellipse insurance solutions portfolio



The chief actuary and the review team

The result must be reproducible, explainable
and appropriate for its intended use.

Today's friction

Repeated extracts, spreadsheet reconciliation and
unclear versions.

The better workflow

A reviewed chain from source data to signed-off
output.

Illustrative role and AI-generated persona. Not a customer or testimonial.



Preparation consumes expert attention

Actuarial transformation starts with the work around the model as well as the model itself.

01

Data preparation

Repeated extracts and unresolved differences.

02

Analysis preparation

Rebuilding assumptions and rerunning changed inputs.

03

Review preparation

Reconstructing how a result was produced.

Data, calculation and review belong together

AegisNow supplies actuarial workflow context, supported by GeneData and Cortex AI.

01

GeneData

Reconciled, versioned inputs
and lineage.

02

AegisNow

Methods, assumptions and
controlled runs.

03

Cortex AI

Evidence retrieval and draft
explanations for review.

A quality score is not a release decision

The accountable data owner determines whether a version can support production work.

01

Measure quality

Check completeness, validity and reconciled totals.

02

Certify the version

Record the owner, purpose and validity period.

03

Handle exceptions

Use a scoped waiver or a restricted exploratory run.

Several methods expose different assumptions

Evaluate the fit of each method against the portfolio and data.

01

Development methods

Chain ladder and
paid/incurred reconciliation.

02

Expected-loss methods

Bornhuetter-Ferguson, Cape
Cod and expected loss ratio.

03

Uncertainty methods

Mack and a reproducible
residual bootstrap.

A range needs a reproducible basis

A stochastic output is useful only with its assumptions and limitations.

01

Stable reproduction

Keep the input, parameters
and random seed.

02

Method diagnostics

Review residuals, sparse
data and tail sensitivity.

03

Responsible interpretation

Explain what the range does
and does not measure.

Experience informs the next assumption set

Connect mortality, lapse and persistency observations with the valuation basis.

01

Prepare exposure

Align observation periods and cohort definitions.

02

Compare experience

Review actual versus expected with credibility.

03

Approve changes

Record the rationale and updated assumption version.

A reviewed pricing basis has several inputs

Prepare analysis that a pricing actuary can explain.

01

Historical basis

Bring premium and losses to a comparable period.

02

Risk components

Review frequency and severity separately.

03

Indication

Apply credibility and record the selected assumptions.

Measurement and movement need a clear trail

AegisNow publicly describes GMM, VFA and PAA calculation support.

01

Model selection

Confirm the appropriate approach and contract grouping.

02

Movement analysis

Reconcile the CSM and relevant components.

03

Finance review

Connect the reviewed output to the close process.

Every run has a recorded basis

Versioning makes a prior result reproducible after the assumptions change.

01

Version

Retain the parameter set and effective context.

02

Separate approval

Distinguish authorship from authorized review.

03

Pin the run

Link each output to the exact input basis.

The intended use defines the validation

A model can be technically executable and still be unsuitable for a decision.

01

Test behavior

Use representative and challenging input cases.

02

Compare results

Investigate unexpected movement and benchmarks.

03

Document limits

Record assumptions, review and unresolved concerns.

Capital planning with a defined scope

Regulatory capital work needs jurisdiction-specific methods, validation and approval.

01

NAIC RBC

Evaluate the described risk-based capital calculation scope.

02

Solvency II SCR

Confirm availability and accepted methods before committing scope.

03

Further capabilities

Scope PBR / VM-20, capital lab and model-drift monitoring separately.

Advanced extensions are not presented as current capabilities. Confirm availability and intended use.

A result includes the record behind it

The review pack should preserve inputs, decisions and limitations.

01

Reproducibility

Data, model, assumptions
and execution context.

02

Review evidence

Diagnostics, comments and
recorded approvals.

03

Sealed record

A verifiable version with
corrections superseding it.

An unexplained movement stops the reporting handoff

An illustrative close reveals a difference between the source extract and the result.

01

Detect

Reconciliation flags the difference.

02

Investigate

The actuary traces the data and model version.

03

Release

The owner approves a corrected, reproducible result.

Illustrative review scenario. Qualified actuarial sign-off remains essential.

A business case your team can measure

Illustrative preparation improvement: eight recurring analyses per month with 25 hours released per analysis.

01

200 hours / month

8 analyses × 25 preparation hours.

02

Quality measures

Reconciliation, reproducibility and review findings.

03

Cost measures

Compute, licensing, validation and ongoing support.

Illustrative planning. Released capacity becomes cash savings only when costs actually reduce.

A roadmap across the actuarial function

The Genellipse catalog includes twelve AI actuarial opportunities.

01

Analysis workflows

Reserving, pricing, capital and valuation preparation.

02

Data and insight

Experience studies, data certification and movement analysis.

03

Controlled reporting

Governance, evidence and reviewed reporting workflows.

A focused MVP within six weeks

Choose one portfolio, a reviewed historical period and an approved method as the comparison baseline.

01

Weeks 1–2

Agree scope, baseline and data access.

02

Weeks 3–4

Configure, connect and test the workflow.

03

Weeks 5–6

Validate with users and decide the next release.

Defined scope and readiness gates apply. Enterprise rollout follows the accepted MVP.

The MVP leaves a reproducible decision record

A working result should be useful to the actuary, finance and technology teams.

Technical evidence

Versioned input, repeatable run and test results.

Professional evidence and operating decision

Assumptions, limitations and recorded review. Measured effort and an agreed expansion plan.



Your next transformation starts with one workflow

Bring one recurring analysis and the preparation steps that take your team away from actuarial judgement.

Genellipse + your team

A shared roadmap, named owners and accountable delivery.

[Genellipse.com](https://www.genellipse.com)

info@genellipse.com

[Back to contents →](#)

